Patients' satisfaction and safety of bulk injection therapy Urolastic for treatment of stress urinary incontinence: A cross-sectional study

Fenne M. Casteleijn1 | Claudia R. Kowalik1 | Claudia Berends1 | Mija Blaganje2 | Mateja Lasić Pecev2 | Ellen van der Linden3 | Sandra E. Zwolsman1 | Jan-Paul W. R. Roovers1 | Pieter Minnee4

Abstract

Aims: Primary outcome was to evaluate patients' satisfaction after being treated with bulk injection therapy polydimethylsiloxane Urolastic (PDMS-U) for stress urinary incontinence (SUI). Secondary outcomes were: subjective cure, objective cure, severity of SUI symptoms, complications, reintervention rate, and disease-specific quality of life. Furthermore, to determine if outcomes worsened during time-after-treatment (time-frames: 0-12, 13-24, and ≥25 months).

Methods: In a cross-sectional design, patients treated with PDMS-U were recruited for hospital revisit. The primary outcome, patients' satisfaction, was assessed by the surgical satisfaction questionnaire. Subjective cure, objective cure, and severity of symptoms were assessed by the patients global impression of improvement, standardized cough stress test, and Sandvik severity scale, respectively. Medical charts and face-to-face interviews were used to determine complications and reinterventions.

Results: About 110 patients participated, 87 revisited the hospital. Median follow-up was 25 months (interquartile range: 14;35 months). Patients' satisfaction rate was 51%. Subjective and objective cure were respectively 46% and 47%. Most prevalent complications were: urinary retention (22%), pain (15%), and dyspareunia (15%). Exposure and erosion occurred in 7% and 5%, respectively. Reintervention rate of reinjection and excision of bulk material was 6% and 18.0%, respectively. Objective cure significantly worsened during time-after-treatment (P = < .05).

Conclusions: About half of the patients being treated with PDMS-U were satisfied and subjectively cured 2 years after treatment, although the majority still experienced symptoms of SUI. Most complications were mild and transient, however, in 18% excision of bulk material was indicated for severe or persistent complications such as pain, exposure, or erosion.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2020 The Authors. Neurourology and Urodynamics published by Wiley Periodicals LLC
INTRODUCTION

Symptoms of urinary incontinence (UI) are highly prevalent and can affect a patient’s quality of life (QoL) severely.\(^1\)\(^2\) When involuntary urine leakage occurs during increased abdominal pressure such as coughing, sneezing, or physical exertion, it is defined as stress UI (SUI) which comprises about half of UI cases.\(^3\)

Behavioral and pharmacological therapies, pelvic floor muscle exercises, vaginal devices (eg, pessary), and surgical options such as synthetic slings, colposuspension, autologous sling surgery, and bulking agents cover the treatment options for female SUI. Consensus statement of the European Urology Association and the European Urogynaecological Association conclude that synthetic slings have a good efficacy and acceptable morbidity, but alternative options must be considered.\(^4\)

Urethral bulk injection therapy is an alternative noninvasive, ambulatory treatment that involves injecting a bulk material transurethral or periurethral, with or without urethroscopic view, in the mucosa of the urethra between the mid-urethra and bladder neck. The injected material gives resistance to the urine flow and thereby aims to prevent leakage of urine, although it is hypothesized that mid-urethral support is needed for the closure mechanism of the urethra as well.\(^5\) To date, randomized controlled trials comparing bulk injection therapy with other surgical options show significant lower objective cure rates regarding urethral bulk injection therapy.\(^6\)\(^7\)

Periurethral injection therapy polydimethylsiloxane Urolastic (PDMS-U) (Urogyn BV Nijmegen, The Netherlands) is one of the latest developed bulking agents and consists of a smooth, non-degradable biocompatible polymer texture. This unique character implies that the bulk material is not absorbed by the body and will stay positioned over time. Using a disposable injecting device, four depots of 0.8 to 1.0 cc are injected periurethral at 2, 5, 7, and 10 O’clock at the mid-urethral level, without cystoscopic control.

From 2011, multiple hospitals have included PDMS-U as a standard treatment option for patients with SUI or mixed urinary incontinence (MUI). Objective and subjective success rates at 6 to 12 months follow-up varied from 59% to 89% and 35% to 90%, respectively.\(^8\)\(^9\)\(^10\) At 2 years follow-up, objective cure rates of 33% to 66% were reported.\(^11\)\(^12\) Although the variety of used study outcomes, patient selection and the learning curve of the physician may have contributed to the wide range, the reported objective cure rate seemed to worsen with longer follow-up. Efficacy rates are in line with bulking agents “Macroplastique” and “Bulkamid” showing subjective success rates of 66% to 90% at 12 months follow-up and objective success rates of 25% to 73%.\(^13\)

As there are no studies that investigated the patients’ satisfaction or safety after 2 years follow-up, we have set up this cross-sectional study in a population of patients that have been treated with PDMS-U from 2014 up to 2018 through standard care. In this retrospective case series our primary aim was to determine patients’ satisfaction. Other outcomes were: subjective cure, objective cure, severity of SUI symptoms, complications and reinterventions, and disease-specific QoL. Second, we aimed to determine if outcomes would worsen during time-after-treatment, following the time frames: 0 to 12 months, 13 to 24 months, and more than 25 months after treatment.

MATERIALS AND METHODS

A multicenter, cross-sectional study was performed in four experienced centers. Site specific information is shown in Appendix 1. To evaluate the influence of a learning curve, only centers that had performed more than 20 PDMS-U procedures were considered to be eligible. The study was reviewed and approved by the ethical committee of all participating centers.

The study population consisted of patients who had been treated with PDMS-U as part of standard care. Women more than or equal to 18 years who received PDMS-U as primary treatment for SUI, secondary for recurrent SUI, or MUI were found eligible. Patients were excluded if they had received PDMS-U for neurogenic bladder, participated in clinical studies or were incapable of giving informed consent.

Enrollment

Patients were informed about the study by a patient information leaflet. Patients who were willing to participate were asked to revisit the hospital. Written informed consent was obtained for subjects on the day of the revisit. Patients who declined participation could give consent to share information from their medical chart by means of an additional informed consent form.

Study procedure

All patients were asked to revisit the hospital where they had been treated. A paper questionnaire was used to
obtain patients characteristics and determine the severity and impact of UI symptoms, complications, and reinterventions. In case patients were unable to revisit the hospital, a paper questionnaire was send to their homes. Patient characteristics, complications, and reinterventions were retracted from the medical charts. Patients who revisited the hospital underwent a face-to-face interview with an independent investigator at the hospital to obtain more information on complications. Physical examination was performed to detect possible exposure of the bulk material and assess the objective cure by means of a standardized cough stress test (CST). Physical examination was performed by the treating doctor, but in presence of an independent investigator, to limit bias.

2.3 | Outcomes

The primary outcome was patients' satisfaction which was determined by three questions from the validated surgical satisfaction questionnaire (SSQ-8): "How satisfied are you with the results for your surgery?", "Looking back, if you had to do it all over again, would you have the surgery again?", and "Would you recommend this surgery to someone else?". Answers of the SSQ questions consisted of a 5-point Likert scale ranging from "very satisfied" to "very unsatisfied" or from "yes" to "never." Patients' satisfaction was defined if answers corresponded with "very satisfied" and "satisfied" or "yes" and "maybe."

Secondary outcomes were: subjective cure, objective cure, severity of SUI symptoms, complications and reinterventions, and disease-specific QoL. Subjective cure was assessed by the patients global impression of improvement (PGI-I). The PGI-I is a validated question to determine the patients improvement of symptoms compared with how it was before the treatment. Answers ranges from "very much better" to "very much worse." We defined patients "subjectively cured" if answers corresponded with: "very much better" or "much better." Objective cure was defined as a negative standardized CST. The CST was performed in lithotomy position with a minimum of 250 mL in the bladder. The Sandvik severity scale (two questions that corresponds with the amount and frequency of UI) and patients global impression of severity (PGI-S) were used to assess the severity of SUI symptoms. Complications were determined by a face-to-face interview and from medical charts. Urinary tract infections (UTI) within 6 weeks after treatment were scored as a complication. Reintervention was defined as any surgical intervention after bulk injection therapy Urolastic to treat recurrent, persistent SUI symptoms or complications. This implied: reinjection of Urolastic, excision of bulk material, suburethral sling surgery or other (surgical) treatments for SUI. The following disease-specific QoL questionnaires were used: International Consultation on Incontinence Questionnaire (ICIQ-short form), Incontinence Impact Questionnaire short form (IIQ-7), and Urogenital Distress Inventory short form (UDI-6).

Patients' satisfaction, subjective cure and objective cure were presented as the time-after-treatment, according to the following time frames: 0 to 12 months, 13 to 24 months, and ≥25 months posttreatment.

2.4 | Statistical analysis

Demographic and baseline characteristics were summarized using standard descriptive methods. Nominal and ordinal data were described using frequencies and percentages. Normally distributed continuous data were described using mean and standard deviation. All used questionnaires were calculated as proposed by the composers. \( \chi^2 \) and Mann-Whitney U were used for categorical data and linear data, respectively. A \( P < .05 \) was considered statistically significant. Statistical analysis has been performed using IBM SPSS Statistics 24.

3 | RESULTS

Eligible patients treated between May 2014 and July 2018 were invited to participate. Figure 1 presents the flowchart of the enrollment. Table 1 shows the patient's and
The mean age was 64 years. The median time after treatment for hospital revisit was 25 months (interquartile range: 14;35 months, range, 1–58 months). Appendix 1 shows overall outcomes and outcomes per study site.

3.1 | Patients’ satisfaction and subjective cure

Patients’ satisfaction was 51%. Sixty-two percent of the patients would have PDMS-U again and 69% would have recommended PDMS-U to someone else. The subjective cure was 46%. Subjective outcomes following time-after-treatment time frames did not significantly differ (Figure 2).

3.2 | Objective cure

The CST was examined in 74 patients and overall 47% (n = 35) were objectively cured. The objective cure decreased significantly following the time-frames 0 to 12, 13 to 24, and more than or equal to 25 months: 77%, 56%, and 35% (P = .02).

3.3 | Severity of SUI symptoms

Overall 85% (n = 74) still experienced symptoms of SUI after PDMS-U treatment; 53% experienced SUI symptoms every day/night and 49% experienced urine leakage “more than droplets.” Incontinence material for SUI symptoms after PDMS-U was used in 47%.
Forty-six percent (n = 40) found the remaining form of UI acceptable, while 17% (n = 15) scored their symptoms of SUI “severe” on the PGI-S.

### 3.4 Complications and reinterventions

Perprocedural complications did not occur. Table 2 represents the postprocedural complications and reinterventions. Overall, 60% (n = 66) encountered postoperative complications. Most prevalent complications were: urinary retention (22%), pain (15%), dyspareunia (15%), and experience of an uncomfortable hard feeling in the vagina (15%). Urinary retention was treated with a catheter-a-demeure or clean intermittent catheterization for a median duration of 4 days. One patient needed excision of the bulk material, 7 days after the procedure to resolve the retention. Eight patients had exposure of bulk material through the vaginal wall. Seven patients were treated with excision of bulk material, in one patient the treatment of the exposure was unknown. None of the patients with exposure showed signs of infection. Hair-like strands of bulk material coming out of the injection site was observed in 13 patients (noticed mostly during the revisit), however, this adverse event was not counted as a complication, as this was a common part of the procedure and did not need any further treatment or were easily removed by tweezers. Erosion of the bulk material to the urethra (n = 2), to the bladder (n = 2), or elsewhere under vaginal wall (n = 2) occurred in six patients. Urethral erosion caused local pain, but could easily be removed by urethroscope. Patients with bladder erosion complained of pain, recurrent UTI’s or hematuria. Both patients were free of complaints after removal of the bulk material by cystoscopic approach. Patients with erosion under the vaginal wall showed a thin epithelial layer and were treated with local estrogen, later excision of the bulk material was still indicated. One patient had a small vaginal abscess 4 days after Urolastic treatment which was treated with antibiotics, followed by excision 2 months later. Other complications were: UTI (n = 8), urgency de novo (n = 7), spontaneous loss of bulk material (n = 3), hematoma (n = 1), and hematuria (n = 1).

Prevalence of reintervention including reinjection, excision, or other reinterventions was 33% (n = 36). Re-injection of PDMS-U was done in seven patients (6%). Median time-after-treatment of re-injection was 4 months (range: 0 days to 18 months). In three patients the re-injection was performed directly after the initial procedure. Five of the seven patients that had undergone re-injection revisited the hospital. At the study visit, four out of five were not subjective and objectively cured and all five patients were unsatisfied with the results. Excision of bulk material was indicated in 18% (n = 20). Median time-after-treatment to excision was 10 months (range: 7 days to 26 months). Reasons for excision were: pain other than dyspareunia (n = 9), exposure (n = 7), erosion (n = 6), persistent SUI (n = 3), dyspareunia (n = 2), recurrent UTI (n = 1), and urinary retention (n = 1). Forty-five percent (n = 9) of the excisions were done under local analgesia and 55% (n = 11) were done under general or spinal anesthesia.

### 3.5 Quality of life

Table 3 shows the scores of disease-specific QoL questionnaires related to the PGI-I. A significant better QoL of UDI-6, IQ-7, and ICIQ-SF was found in patients with improved symptoms (P < .01).
Appendix 2, an overview of subgroup analysis on patient characteristics, showed that clinical success and satisfaction was not influenced by patient’s age or body mass index. Patients who have had previous surgery before PDMS-U were more likely to be objectively cured compared with patients with no prior or only conservative treatment (61% vs 37%; \( P = .04 \)). Patients undergoing PDMS-U as secondary intervention did not encounter more complications (61% vs 58%; \( P = .686 \)). Regarding the physicians learning curve, patients of the first 20 procedures were more likely to be satisfied compared with the patients more than 20 procedures (61% vs 37%; \( P = .04 \)). Patients undergoing PDMS-U as secondary intervention did not encounter more complications (61% vs 58%; \( P = .686 \)).

No statistically significant differences were found regarding the procedure number and complication rate (66% vs 57%; \( P = .403 \)), nor for subjective cure or objective cure. Analysis on site dependent outcomes showed that only site 2 had higher objective cure rates compared with site 3 (odds ratio, 8.69; \( P < .01 \)).

**DISCUSSION**

In this study, we primarily evaluated the patients’ satisfaction being treated with PDMS-U for SUI. Second, we assessed the subjective cure, objective cure, severity of symptoms, complications, and reintervention rate and disease-specific QoL. Although 85% of the patients still experienced symptoms of SUI after a median period of 25 months, 51% were satisfied with the results and 69% would recommend the treatment to someone else. The patients’ satisfaction and subjective cure remained stable during time-after-treatment up to more than or equal to 25 months, whereas objective cure significantly worsened over time. Although reinjection of PDMS-U is an common option to improve outcomes, this was only done in 6% and the outcomes did not improve. Urinary retention, pain, and dyspareunia were the most prevalent complications. Excision of bulk material to treat severe or persistent complications such as pain, exposure or erosion was indicated in 18%.

Our study shows that almost half of the patients were satisfied after PDMS-U, 34% were not. The high number of SUI symptoms after treatment (85%), relative high chance to encounter complications (60%), and undergo a reintervention (33%) can contribute to dissatisfaction. The results on subjective and objective cure are comparable with other studies regarding PDMS-U. Kowalik et al included patients with complicated SUI with a poor expected outcome and reported an equal subjective cure rate of 50% at 6 months follow-up. Another study performed a telephonic survey among patients treated with Urolastic for regular care in a general hospital and tertiary referral hospital. The subjective cure of the general hospital with a median follow-up time of 12 months was higher (61% vs 50%), but the subjective cure of the tertiary referral hospital after a median follow-up of 25 months was similar (43% vs 46%). The objective cure, also assessed by the CST, showed a similar decreasing trend corresponding with time-after-treatment of 6 months, 12 months, and 24 months follow-up (65%, 59%, and 33%). In conclusion,

| TABLE 2 Complications and reinterventions |
|------------------------------------------|
| Adverse events                           | Total 110 |
| Urinary retention                        | 24 21.8   |
| CAD for <48 h                            | 7 29.2    |
| CAD for ≥48 h                            | 13 54.2   |
| Unknown                                  | 3 12.5    |
| Pain                                     | 16 14.5   |
| Dyspareunia                              | 16 14.5   |
| Uncomfortable hard feeling vagina        | 16 14.5   |
| Urinary tract infection                  | 10 9.1    |
| Exposure (through vaginal wall)          | 8 7.3     |
| Urgency incontinence de novo             | 7 6.4     |
| Erosion (through urethra or bladder)     | 6 5.4     |
| Spontaneous loss bulk material           | 3 2.7     |
| Infection at injection site              | 1 0.9     |
| Hematuria                                | 1 0.9     |
| Hematoma at injection site               | 1 0.9     |
| Reinterventions                          |           |
| Excision of Urolastic                    | 20 18.1   |
| 2 O’clock location                       | 4 20      |
| 5 O’clock location                       | 8 40      |
| 7 O’ clock location                      | 11 55     |
| 10 O’clock location                      | 5 25      |
| Unknown location                         | 1 0.5     |
| Other location                           | 5 25      |
| Reinjection                              | 7 6.3     |
| MUS-operation after Urolastic treatment  | 6 5.5     |
| Other reintervention                      | 3 2.7     |

Note: Overview of complications and reinterventions.

Pain urogenital area ≥2 wk after treatment, other than dyspareunia.

An uncomfortable feeling of the presence of bulk material during daily activities without pain.

Other location of excision: bladder (n = 2), para-urethral left (n = 2), para-urethral left, and right (n = 1).

Rectus fascia sling (n = 1), PFMT (n = 1), and excision hematoma (n = 1).

Abbreviations: CAD, catheter a demeure; MUS, mid-urethral sling; PFMT, pelvic floor muscle training

### 3.6 Subgroup analysis

Appendix 2, an overview of subgroup analysis on patient characteristics, showed that clinical success and satisfaction was not influenced by patient’s age or body mass index. Patients who have had previous surgery before PDMS-U were more likely to be objectively cured compared with patients with no prior or only conservative treatment (61% vs 37%; \( P = .04 \)). Patients undergoing PDMS-U as secondary intervention did not encounter more complications (61% vs 58%; \( P = .686 \)). Regarding the physicians learning curve, patients of the first 20 procedures were more likely to be satisfied compared with the patients more than 20 procedures (75% vs 41%; \( P = .01 \)). No statistically significant differences were found regarding the procedure number and complication rate (66% vs 57%; \( P = .403 \)), nor for subjective cure or objective cure. Analysis on site dependent outcomes showed that only site 2 had higher objective cure rates compared with site 3 (odds ratio, 8.69; \( P < .01 \)).
patients can be satisfied while having persistent symptoms of SUI.

Bulk injection therapy is known for the attractive safety profile, with having less complications as compared with open surgery. Complications occur in one out of three patients and are mostly transient without requiring surgical treatment. Our study shows a higher risk of complications (60% vs 24%) and higher number of reinterventions (18% vs 11%) compared with PDMS-U outcomes reported in a systematic review. This could be due to the fact that the follow-up in our study was longer so the chance on a complication was higher. To improve the acceptance of PDMS-U for patients, future studies can look into options to lower the number of operative reinterventions, for example, inject a lower amount bulk material, determine the ideal position of the bulk material, and if necessary adapt the injection device to achieve this. For example, although we reported patients with “erosion,” it is not certain whether migration of the bulk material resulted in erosion or that the bulk material was initially injected too superficial under the epithelial layer or in the urethra or bladder.

In this study, we have evaluated the learning curve of the physician. Subgroup analysis remarkably showed that patients of procedure number 0 to 20 were more satisfied with results than patients of procedure number more than 20, while objective cure or complication rate did not differ. Because in general physicians learn a procedure, beginning with the most complicated patients that already have undergone multiple treatments, it could be that these patients were more easy satisfied.

This study has several limitations. First, inherent to the nature of a cross-sectional design, some patients were not willing to participate or did not respond. Hence, it is uncertain whether our findings are representative for the whole population of women indicated for a bulking agent. Second, lack of preoperative data is a major limitation that could have affected the interpretation of outcomes. Missing information on micturition status or inaccurate recall by the patient made it uncertain to what extent symptoms have improved. Third, the retrospective data collection from medical charts could be insufficient, especially complications may have been under-reported. Fourth, one should be careful to interpret the outcomes of the objective cure, because the baseline measurements were not available. Finally, one could argue that validated questionnaires such as the ICIQ-SF have no additional value when assessed only after surgery. However, a strong correlation between PGI-I and ICIQ-SF as well as validation of a cutoff score of the ICIQ-SF postoperatively have been reported.

The European Union medical device regulation has set several goals regarding legislation, among other to strengthening postmarketing surveillance and risk evaluation. PDMS-U has been in the market for several years and although cohort studies have been performed, no study has evaluated this product for over 2 years follow-up, like we did. This is the first study that also evaluated patients’ satisfaction and long-term safety assessment of PDMS-U. As we obtained data from standard care, the results are generalizable and useful to counsel patients about satisfaction and safety of SUI treatment with PDMS-U.

### 5 CONCLUSIONS

About half of the patients being treated with PDMS-U were satisfied and subjectively cured 2 years after treatment, although the majority still experienced symptoms of SUI. Most complications were mild and transient, however, in 18% excision bulk material was indicated for severe or persistent complications such as pain, exposure, or erosion.

### TABLE 3 Disease-specific quality of life

|                          | Improved     | Similar      | Worsened    | P-value |
|--------------------------|--------------|--------------|-------------|---------|
| UDI-6 total mean (SD)    | 29.2 ± 18.7  | 44.1 ± 17.7  | 52.3 ± 25.1 | <.01    |
| Irritative subscale      | 31.1 ± 28.5  | 46.0 ± 26.8  | 60.3 ± 30.1 | <.01    |
| Stress subscale          | 38.8 ± 26.6  | 54.9 ± 27.5  | 65.3 ± 29.7 | <.01    |
| Obstructive subscale     | 18.3 ± 19.1  | 31.4 ± 35.3  | 37.2 ± 28.8 | .17     |
| ICIQ-7 total mean (SD)   | 22.6 ± 22.1  | 40.1 ± 29.0  | 47.9 ± 29.9 | <.01    |
| Physical activity        | 23.9 ± 22.8  | 35.4 ± 34.9  | 50.0 ± 31.8 | .03     |
| Mobility                 | 22.1 ± 26.1  | 39.6 ± 35.9  | 46.2 ± 36.1 | .03     |
| Social function          | 25.2 ± 31.9  | 41.2 ± 38.2  | 53.8 ± 34.8 | .02     |
| Emotional health         | 18.6 ± 23.5  | 39.2 ± 38.6  | 53.8 ± 32.7 | <.01    |

Disease-specific quality of life related to improved, similar or worsened outcome on the Patient Global Impression of Improvement (PGI-I) scale.

Abbreviations: ICIQ-SF, International Consultation on Incontinence Questionnaire Short Form; ICIQ-7, Incontinence Impact Questionnaire; SD, standard deviation; UDI-6, Urogenital Distress Inventory.
ACKNOWLEDGMENT

A nonrestricted grand from Urogyn BV The Netherlands was given.

ORCID
Fenne M. Casteleijn @ http://orcid.org/0000-0002-8220-9742
Claudia R. Kowalik @ http://orcid.org/0000-0003-0802-1116

REFERENCES

1. van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int. 2002;90(6):544-549.

2. van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP. The influence of urinary incontinence on quality of life of community-dwelling, 45-70 year old Dutch women. Ned Tijdschr Geneesk. 2000;144(19):894-897.

3. Hannotstad YS, Rortveit G, Sandvik H, Hunskaar S. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the county of Nord-Trondelag, J Clin Epidemiol. 2000;53(11):1150-1157.

4. Chapple CR, Cruz F, Deffieux X, et al. Consensus statement of the European Urology Association and the European Urogynaecological Association on the use of implanted materials for treating pelvic organ prolapse and stress urinary incontinence. Eur Urol. 2017;72(3):424-31.

5. de Vries AM, Venema PL, Heesakkers J. Midurethral support is also necessary for reflex closure of the urethra. Neurourol Urodyn. 2018;37(8):2965-72.

6. Kirchin V, Page T, Keegan PE, et al. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev. 2017;7:CD003881.

7. Ikonen Freitas AM, Mentula M, Rahkola-Soisalo P, Tulokas S, Mikkola TS. Tension-free vaginal tape surgery versus polyacrylamide hydrogel injection for primary stress urinary incontinence: a randomized clinical trial. J Urol. 2020;203(2):372-378.

8. Kowalik CR, Casteleijn FM, van Eijndhoven HWF, Zwolsman SE, Roovers JWR. Results of an innovative bulking agent in patients with stress urinary incontinence who are not optimal candidates for mid-urethral sling surgery. Neurourol Urodyn. 2018;37(1):339-345.

9. Futyma K, Miotła P, Galczynski K, et al. An open multicenter study of clinical efficacy and safety of urolastic, an injectable implant for the treatment of stress urinary incontinence: one-year observation. BioMed Res Int. 2015;2015:851823-851825.

10. Zajda J, Farag F. Urolastic‐a new bulking agent for the treatment of women with stress urinary incontinence: outcome of 12 months follow up. Adv Urol. 2013;2013:724082.

11. Zajda J, Farag F. Urolastic for the treatment of women with stress urinary incontinence: 24-month follow-up. Cent Eur J Urol. 2015;68(3):334-338.

12. Futyma K, Nowakowski L, Galczynski K, Miotła P, Rechberger T. Nonabsorbable urethral bulking agent - clinical effectiveness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up. Eur J Obstet Gynaecol Reprod Biol. 2016;207:68-72.

13. Siddiqui ZA, Abboudi H, Crawford R, Shah S. Intravesical bulking agents for the management of female stress urinary incontinence: a systematic review. Int Urogynecol J. 2017;28(9):1275-84.

14. de Vries AM, Wadhwa H, Huang J, Farag F, Heesakkers J, Kocjaniec E. Complications of urethral bulking agents for stress urinary incontinence: an extensive review including case reports. Female Pelvic Med Reconstr Surg. 2018;24(6):392-398.

15. Haff RE, Stoltzfus J, Lucente VR, Murphy M. The Surgical Satisfaction Questionnaire (SSQ-8): a validated tool for assessment of patient satisfaction following surgery to correct prolapse and/or incontinence. J Minim Invasive Gynecol. 2011;18(6):49-50.

16. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189(1):98-101.

17. Sandvik H, Hunskaar S, Seim A, Hermstad R, Vanvik A, Bratt H. Validation of a severity index in female urinary incontinence and its implementation in an epidemiological survey. J Epidemiol Community Health. 1993;47(6):497-499.

18. Klovning A, Avery K, Sandvik H, Hunskaar S. Comparison of two questionnaires for assessing the severity of urinary incontinence: the ICIQ‐UI SF versus the incontinence severity index. Neurourol Urodyn. 2009;28(5):411-415.

19. Uebersax JS, Wyman JF, Shumaker SA, McClark DK, Fanl JA. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continece Program for Women Research Group. Neurourol Urodyn. 1995;14(2):131-139.

20. de Vries AM, van Breda HMK, Fernandes JG, Venema PL, Heesakkers J. Para-urethral injections with urolastic(R) for treatment of female stress urinary incontinence: subjective improvement and safety. Urol Int. 2017;99(1):91-97.

21. Kocjaniec E, Mourad S, Acar O. Complications of urethral bulking therapy for female stress urinary incontinence. Neurourol Urodyn. 2019;38.

22. Karmakar D, Mostafa A, Abdel-Fattah M. A new validated score for detecting patient-reported success on postoperative ICIQ-SF: a novel two-stage analysis from two large RCT cohorts. Int Urogynecol J. 2017;28(1):95-100.

23. Council of the European Union EP. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC Publications Office of the European Union. 2017.

How to cite this article: Casteleijn FM, Kowalik CR, Berends C, et al. Patients’ satisfaction and safety of bulk injection therapy Urolastic for treatment of stress urinary incontinence: A cross-sectional study. Neurourology and Urodynamics. 2020;39:1753–1763. https://doi.org/10.1002/nau.24417
### TABLE A1  Overview outcomes per site

| Patient characteristics                  | Overall | Site 1 | Site 2 | Site 3 | Site 4 |
|------------------------------------------|---------|--------|--------|--------|--------|
| Eligible patients                        | 202     | 65     | 64     | 57     | 16     |
| Included patients                        | 110     | 25     | 36     | 40     | 9      |
| Filled out questionnaire                 | 87      | 25     | 36     | 24     | 2      |
| Age mean (SD)                            | 64 ± 13 | 61 ± 10.6 | 64 ± 12 | 63 ± 14.4 | 77.4 ± 6.3 |
| No surgery before PDMS-U n (%)           | 70 (64) | 11 (44) | 10 (27.8) | 37 (92.5) | 9 (100) |
| With surgery before PDMS-U n (%)         | 40 (36) | 14 (56) | 26 (69.4) | 3 (7.5) | 0 (0) |
| Mixed urinary incontinence n (%)         | 59 (54) | 10 (0.4) | 22 (61.1) | 19 (47.5) | 8 (88.9) |

| Procedural characteristics               |         |        |        |        |        |
|------------------------------------------|---------|--------|--------|--------|--------|
| Amount (cc) of injected bulk material per location in median (range) |         |        |        |        |        |
| 2 O'clock                                | 1.0 (0.4-1.2) | 0.8 (0.6-0.8) | 1.0 (0.8-1.2) | 1.0 (0.4-1.0) | 1.0 (0.8-1.0) |
| 5 O'clock                                | 1.0 (0.0-1.2) | 1.0 (0.8-1.2) | 1.0 (0.0-1.2) | 0.8 (0.4-1.0) | 1.0 (0.8-1.0) |
| 7 O'clock                                | 1.0 (0.0-1.2) | 1.0 (0.8-1.2) | 1.0 (0.0-1.2) | 0.8 (0.4-1.0) | 1.0 (0.8-1.0) |
| 10 O'clock                               | 0.8 (0.0-1.2) | 0.8 (0.6-0.8) | 1.0 (0.8-1.2) | 1.0 (0.4-1.0) | 0.8 (0.0-1.0) |
| Time-after-treatment median (IQR)         | 25 (14;35) | 34 (25;38) | 13 (7;18) | 33 (28;40) | 31 (34;-) |
| 0-12 mo n (%)                            | 21 (18) | 0 (0) | 17 (47) | 1 (4.2) | 0 (0) |
| 13-24 mo n (%)                           | 29 (25) | 4 (16) | 19 (53) | 2 (8.3) | 0 (0) |
| >24 mo n (%)                             | 51 (44) | 21 (84) | 0 (0) | 21 (87.5) | 2 (100) |

| Site and physician characteristics       |         |        |        |        |        |
|------------------------------------------|---------|--------|--------|--------|--------|
| Type of hospital                         |         |        |        |        |        |
| Academic hospital                        | Gynecologist |           |          |          |        |
| General hospital                         | Urologist         |          |          |          |        |
| Teaching hospital                        | Urologist         |          |          |          |        |
| Total performed Urolastic procedures     | 67      | 67     | 57     | 23     |        |

| Outcomes                                 | Overall | Site 1 | Site 2 | Site 3 | Site 4 |
|------------------------------------------|---------|--------|--------|--------|--------|
| SSQ-8: “How satisfied are you with the results for your surgery?” n (%) |         |        |        |        |        |
| Very satisfied                           | 22 (25.3) | 6 (24) | 10 (27.7) | 5 (20.8) | 1 (50) |
| Satisfied                                | 22 (25.3) | 4 (16) | 10 (27.7) | 8 (33.3) | 0 (0) |
| Neutral                                  | 13 (14.9) | 3 (12) | 7 (19.4) | 3 (12.5) | 0 (0) |
| Unsatisfied                               | 24 (27.6) | 9 (36) | 8 (22.2) | 6 (25) | 1 (50) |
| Very unsatisfied                         | 6 (6.9) | 3 (12) | 1 (2.7) | 2 (8.3) | 0 (0) |
| Satisfaction rate n (%)                  | 44 (51) | 10 (40) | 20 (55.6) | 13 (54.2) | 1 (50) |
| SSQ-8: “Looking back, if you had to do it all over again, would you have the surgery again?” n (%) |         |        |        |        |        |
| Yes                                      | 46 (52.9) | 12 (48) | 22 (61.1) | 11 (45.8) | 1 (50) |
| Maybe                                    | 8 (9.2) | 1 (4) | 2 (5.5) | 5 (20.8) | 0 (0) |
| Unsure                                    | 8 (9.2) | 1 (4) | 5 (13.8) | 2 (8.3) | 0 (0) |
| I don’t think so                         | 15 (17.2) | 5 (20) | 6 (16.6) | 3 (12.5) | 1 (50) |
| Never                                    | 10 (11.5) | 6 (24) | 1 (2.7) | 3 (12.5) | 0 (0) |
| SSQ-8: “Would you recommend this surgery to someone else?” n (%) |         |        |        |        |        |
| Yes                                      | 51 (58.6) | 11 (44) | 23 (63.8) | 16 (66.7) | 1 (50) |
| Maybe                                    | 9 (10.3) | 2 (8) | 4 (11.1) | 3 (12.5) | 0 (0) |
| Unsure                                    | 13 (14.9) | 6 (24) | 6 (16.6) | 1 (4.1) | 0 (0) |
| I don’t think so                         | 8 (9.2) | 3 (12) | 2 (5.5) | 2 (8.5) | 1 (50) |
| Never                                    | 6 (6.9) | 3 (12) | 1 (2.7) | 2 (8.3) | 0 (0) |
| Overall | Site 1 | Site 2 | Site 3 | Site 4 |
|---------|--------|--------|--------|--------|
| **Patient global impression of improvement (PGI-I) n (%)** | | | | |
| Very much better | 22 (25.3) | 4 (16) | 12 (33.3) | 6 (25) | 0 (0) |
| Much better | 18 (20.7) | 3 (12) | 8 (22.2) | 6 (25) | 1 (50) |
| A little better | 17 (19.5) | 5 (20) | 6 (16.6) | 6 (25) | 0 (0) |
| No change | 17 (19.5) | 7 (28) | 7 (19.4) | 3 (12.5) | 0 (0) |
| A little worse | 3 (3.4) | 1 (4) | 1 (2.8) | 0 (0) | 1 (50) |
| Much worse | 6 (6.9) | 3 (12) | 2 (5.5) | 1 (4.2) | 0 (0) |
| Very much worse | 4 (4.6) | 2 (8) | 0 (0) | 2 (8.3) | 0 (0) |
| **Subjective cure n (%)** | 40 (46) | 7 (28) | 20 (55.6) | 12 (50) | 1 (50) |
| **Still have symptoms of stress urinary incontinence (%)** | 74 (85) | 24 (96) | 30 (83) | 18 (70) | 2 (100) |
| **Sandvik severity scale: frequency of urinary incontinence n (%)** | | | | |
| Less than one time a month | 4 (4.6) | 1 (4) | 3 (8.3) | 0 (0) | 0 (0) |
| Once or a few times a month | 11 (12.6) | 5 (20) | 4 (11.1) | 2 (8.3) | 0 (0) |
| Once or a few times a week | 15 (17.2) | 6 (24) | 5 (13.8) | 4 (16.7) | 0 (0) |
| Every day/night | 46 (52.9) | 13 (52) | 20 (55.5) | 11 (45.8) | 2 |
| **Amount of urinary incontinence n (%)** | | | | |
| Droplets | 32 (36.8) | 13 (52) | 13 (36.1) | 6 (25) | 0 (0) |
| More than droplets | 43 (49.4) | 12 (48) | 17 (47.2) | 12 (50) | 2 (100) |
| **Patient global impression of severity (PGI-S) n (%)** | | | | |
| Not applicable, I don't have voiding problems | 0 (0) | 13 (36.1) | 1 (4.2) | 0 (0) |
| Normal | 5 (5.7) | 9 (36) | 3 (8.3) | 11 (45.8) | 1 (50) |
| Mild | 24 (27.6) | 11 (44) | 12 (33.3) | 5 (20.8) | 1 (50) |
| Moderate | 29 (33.3) | 4 (16) | 7 (19.4) | 4 (16.7) | 0 (0) |
| Severe | 15 (17.2) | 1 (4) | 1 (2.7) | 3 (12.5) | 0 (0) |
| **Objective cure n (%)** | 35/74 (47.3) | 8/25 (32) | 19/24 (79.2) | 7/23 (30.4) | 1/2 (50) |
| **Complications and reinterventions n (%)** | | | | |
| Urinary retention | 24 (21.8) | 1 (4) | 10 (27.7) | 8 (20) | 5 (56) |
| Pain | 16 (14.5) | 5 (20) | 3 (8.3) | 4 (10) | 4 (44) |
| Dyspareunia | 16 (14.5) | 7 (28) | 4 (11.1) | 5 (20.8) | 0 (0) |
| Uncomfortable hard feeling | 16 (14.5) | 5 (20) | 5 (13.8) | 4 (10) | 2 (22) |
| Urinary tract infection | 10 (9.1) | 0 (0) | 6 (16.6) | 2 (5) | 2 (22) |
| Urgency de novo | 7 (6.4) | 3 (12) | 0 (0) | 4 (10) | 0 (0) |
| Exposure | 8 (7.3) | 2 (8) | 3 (8.3) | 1 (2.5) | 2 (22) |
| Erosion | 6 (5.4) | 2 (8) | 0 (0) | 2 (5) | 2 (22) |
| Reinjection | 7 (6.3) | 1 (4) | 0 (0) | 3 (7.5) | 3 (33) |
| Excision | 20 (18.1) | 6 (24) | 4 (11.1) | 6 (15) | 4 (44) |
| **ICIQ-SF-score mean (SD)** | 11.5 ± 5.4 | 12.9 ± 5.2 | 10.6 ± 5.6 | 11.1 ± 5.6 | 13 ± 2.8 |
| **IIQ-SF-score mean (SD)** | 30.0 ± 26.6 | 39.0 ± 29.7 | 25.0 ± 23.5 | 25.9 ± 26.5 | 37.5 ± 11.8 |
| **UDI-score mean (SD)** | 35.7 ± 21.4 | 43.3 ± 22.8 | 31.3 ± 18.9 | 32.4 ± 21.1 | 47.2 ± 27.5 |

Note: Total overview of outcomes per study site: patients’ satisfaction, PGI-I, Sandvik severity scale, PGI-S, objective cure, complications, reinterventions, and quality of life.

Abbreviations: ICIQ, International Consultation on Incontinence Questionnaire Short Form; IIQ, Incontinence Impact Questionnaire Short Form; IQR, interquartile range; PDMS-U, polydimethylsiloxane-Urolastic; PGI-I, patients global impression of improvement; PGI-S, patients global impression of severity; SD, standard deviation; SSQ-8, Surgical Satisfaction Questionnaire; UDI, Urogenital Distress Inventory Short Form.
## APPENDIX 2

### Table A2 Subgroup analysis

| Subanalysis for patient characteristics | Objective cure | Subjective cure | Satisfied |
|-----------------------------------------|----------------|-----------------|-----------|
| Age, continuous\(^a\)                  | 0.34           | 0.92            | 0.11      |
| Age (median, IQR)                       | 66.0 (60.0-74.0)| 64.0 (56.8-70.8) | 66.5 (59.5-72.0) |
| Age, categorical (p)\(^b\)              | 0.12           | 0.74            | 0.29      |
| Lowest-50 (n,%)\(^c\)                  | 3 (33.3)       | 5 (38.5)        | 4 (38.8)  |
| 50-75 (n,%)\(^c\)                      | 25 (44.6)      | 31 (38.4)       | 34 (39.1) |
| >75-highest (n,%)\(^c\)                | 7 (77.8)       | 4 (40.0)        | 6 (60.0)  |
| BMI, continuous\(^a\)                  | 0.51           | 0.81            | 0.71      |
| BMI (median, IQR)                       | 26.9 (24.2-29.4)| 26.5 (24.4-30.1)| 27.2 (24.4-30.1) |
| BMI, categorical (p)\(^b\)              | 0.53           | 12 (46.2)       | 0.97      |
| 0-25 (n,%)\(^c\)                       | 11 (52.4)      | 27 (45.8)       | 12 (46.2) |
| >25 (n,%)\(^c\)                        | 23 (44.2)      | 31 (52.5)       |           |
| MUI vs SUI (p)\(^b\)                   | 0.80           | 20 (43.5)       | 0.62      |
| MUI (n,%)\(^c\)                        | 19 (48.7)      | 20 (48.8)       | 22 (47.8) |
| SUI (n,%)\(^c\)                        | 16 (45.7)      |                | 22 (53.7) |
| No surgery before PDMS-U vs with surgery before PDMS-U (p)\(^b\) | 0.04           | 0.27            | 0.44      |
| No surgery before PDMS-U (n,%)\(^c\)   | 16 (37.2)      | 20 (40.8)       | 23 (46.9) |
| With surgery before PDMS-U (n,%)\(^c\) | 19 (61.3)      | 20 (52.6)       | 21 (55.3) |

Subanalyses for procedural characteristics

| Procedure 1-20 vs >20 (p)\(^b\)      | 0.42       | 0.06 | <0.01 |
| 1-20 (n,%)\(^c\)                    | 12 (54.5)  | 15 (62.5) | 18 (75) |
| >20 (n,%)\(^c\)                     | 23 (44.2)  | 25 (39.7) | 26 (41.3) |

Subanalyses per center

| Center (p)\(^b\)         | <0.01 | 0.19 |
| 1\(^d\) (n,%)\(^c\)      | 8 (32) | 7 (28) | 10 (40) |
| 2\(^d\) (n,%)\(^c\)      | 19 (79.2)| 20 (55.6)| 20 (55.6) |
| 3\(^d\) (n,%)\(^c\)      | 7 (30.4)| 12 (50) | 13 (54.2) |
| 4\(^d\) (n,%)\(^c\)      | 1 (50)  | 1 (50)  | 1 (50)   |

Note: Total overview of outcomes per study site: objective cure, subjective cure, and satisfaction.
Abbreviations: BMI, body mass index; IQR, interquartile range; MUI, mixed urinary incontinence; PDMS-U, polydimethylsiloxane-Urolastic; SUI; stress urinary incontinence.
\(^a\)Mann-Whitney U.
\(^b\)\(\chi^2\).
\(^c\)Percentages presented as within categorical group.
\(^d\)Site 1: Academic hospital.
\(^e\)Site 2: General hospital.
\(^f\)Site 3: General hospital.
\(^g\)Site 4: Teaching hospital.